Cardiac damage and long COVID
These signs of heart injury are attributed by some cardiologists. High troponin levels in Hospitalized COVID-19 patients continued to promote myocardial scarring even in the absence of edema, demonstrating that the virus's harm is irreversible and placing them at an increased risk of heart failure.
The requirement to pump blood through inflamed lungs puts strain on the right side of the heart. This strain is frequently made worse by the development of blood clots in the blood arteries of the heart and lungs, which coupled with the inflammation lower the degree of oxygenation in these crucial organs. Higher positive end-expiratory pressure during mechanical breathing, which stresses the right ventricle, may make this worse.
COVID-19 in pre-existing heart failure
In pre-existing heart failure, COVID-19
The prognosis is bad for those who already have heart failure because the presence of COVID-19 can lead to myocardial damage and sudden cardiac failure in these patients. The cytokine storm associated with severe COVID-19, which includes high levels of interleukin (IL) such IL3, IL6, IL7, and other inflammatory mediators, is likely the cause of heart failure.
High amounts of cytokines may result in stress cardiomyopathy and cardiac dysfunction. Even in patients whose heart failure was previously stable, this causes abrupt decompensation.
Acute respiratory distress syndrome (ARDS) and pneumonia are lung-related conditions where ACE inhibitors may have a favorable effect during COVD-19, but their role should be assessed to avoid any negative effects. Azithromycin and hydroxychloroquine are two medications that should be properly managed, especially if the patient has structural heart disease or coronary artery disease. These medications may also cause arrhythmias when there is an electrolyte imbalance and other risk factors present.
Heart injury with a prolonged COVID
Following COVID-19, signs and symptoms of potential cardiac injury can include post-exertional exhaustion, postural orthostatic tachycardia syndrome (POTS), palpitations, chest pain, shortness of breath, and increased troponin levels with abnormal electrocardiograms, which may signify a heart attack.
Myocarditis
At least in some people with COVID-19, heart inflammation appears to be prevalent. The myocardial and pericarditis may both be affected, which would result in extreme weariness without any other noticeable symptoms.
In COVID-19, myocarditis is frequently fulminant and largely self-resolving, although it can occasionally lead to arrhythmias, heart failure, cardiac arrest, and unexpected death. Cardiogenic shock is the cause of death in this case.
The diagnosis of myocarditis is relatively inaccurate because both tests and diagnostic protocols are lacking. The course of the illness is therefore unknown at present, but some early reports have shown that symptoms lingered for a median of 47 days before diagnosis was accomplished by cardiac magnetic resonance (CMR) imaging.
In one study, edema, a sign of active inflammation, was present in more than half of the patients, and many also showed scarring and reduced right ventricular function.
Since other viral respiratory illnesses are not monitored using CMR or troponin, the data is insufficient to allow a valid comparison between COVID-19 and this data or to conclusively say that the abnormalities are a specific sequel of COVID-19.
However, in a different German trial that exclusively included patients whose viral clearance was established by a negative nasal swab, up to 60% of patients still displayed symptoms of cardiac inflammation after 2 - 3 months. More still had elevated troponin levels. When compared to controls, this study found evidence of enlarged hearts and ineffective pumping.
In a few patients who showed significant alterations on CMR, active inflammation was confirmed. With a mean age of under 50 years, the majority of the patients in this study were not hospitalized, including a few who had no symptoms. Heart inflammation risk was unrelated to the severity of COVID-19, underlying medical problems, or time since onset.
In one study, athletes who had recovered from COVID-19 exhibited the same myocarditis symptoms whether they were currently ill or had just recovered. In this study, 12/26 competitive athletes showed these features at up to 53 days from quarantine.
Notably, the German trial included many numerous patients who may have experienced myocarditis-related symptoms, which could have influenced the results. When compared to controls who were matched for the same risk variables as the patients, many of the patients with aberrant imaging findings had borderline positive results.
The data is insufficient to allow a meaningful comparison between COVID-19 and this data or to definitively state that the abnormalities are a specific consequence of COVID-19 because other viral respiratory infections are not studied using CMR or troponin.
In viral infections, myocarditis often results from a direct infection of the heart muscle, but in COVID-19, it may also be caused by cytokines that are circulated as a result of systemic inflammation. The latter could explain the arrhythmias and even cardiac ischemia events that happen as a result of plaque rupture and plaque pieces obstructing the heart arteries.
Monkey models that reveal scarring of the heart in recovered infected monkeys but not in controls lend credence to this theory.
You must be logged in to post a comment.